-1651085832.png){kind=logo}
Home
HelpTest Code BAP Bone Alkaline Phosphatase, Serum
Additional Codes
CNE Order Code: Bone Spec Alk Phos
Reporting Name
Bone Alkaline Phosphatase, SUseful For
Diagnosis and assessment of severity of metabolic bone disease including Paget disease, osteomalacia, and other states of high bone turnover
Monitoring efficacy of antiresorptive therapies including postmenopausal osteoporosis treatment
The assay is not intended as a screening test for osteoporosis.
Measurements of bone turnover markers are not useful for the diagnosis of osteoporosis; diagnosis of osteoporosis should be made based on bone density.
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
SerumSpecimen Required
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.6 mL
Collection Instructions: Centrifuge and aliquot serum into plastic vial.
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Refrigerated (preferred) | 14 days | |
| Frozen | 90 days | ||
| Ambient | 7 days |
Reference Values
Males
<2 years: 25-221 mcg/L
2-9 years: 27-148 mcg/L
10-13 years: 35-169 mcg/L
14-17 years: 13-111 mcg/L
Adults: ≤20 mcg/L
Females
<2 years: 28-187 mcg/L
2-9 years: 31-152 mcg/L
10-13 years: 19-177 mcg/L
14-17 years: 7-41 mcg/L
Adults
Premenopausal: ≤14 mcg/L
Postmenopausal: ≤22 mcg/L
Day(s) Performed
Monday through Saturday
CPT Code Information
84080
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| BAP | Bone Alkaline Phosphatase, S | 17838-4 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| BAP | Bone Alkaline Phosphatase, S | 17838-4 |
Interpretation
Bone alkaline phosphatase (BAP) concentration is high in Paget disease and osteomalacia.(3)
Antiresorptive therapies lower BAP from baseline measurements in Paget disease, osteomalacia, and osteoporosis. Several studies have shown that antiresorptive therapies for management of osteoporosis patients should result in at least a 25% decrease in BAP within 3 to 6 months of initiating therapy.(4,5) BAP also decreases following antiresorptive therapy in Paget disease.(6)
When used as a marker for monitoring purposes, it is important to determine the critical difference (or least significant change). The critical difference is defined as the difference between 2 determinations that may be considered to have clinical significance. The critical difference for this method was calculated to be 25% with a 95% confidence level.(1)
Report Available
2 to 3 daysReject Due To
| Gross hemolysis | Reject |
| Gross lipemia | OK |
Method Name
Immunoenzymatic Assay